GSK set to cut prices in more emerging markets
This article was originally published in Scrip
GlaxoSmithKline is moving ahead with plans to expand a programme of price cuts for selected products from Asia to other emerging markets, CEO Andrew Witty has said.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.